adminの記事一覧

Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.

Am J Nephrol. 25(5): 447-450, 2005.PubMed

Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.

J Lab Clin Med. 145(3): 125-133, 2005.PubMed

Urinary excretion of liver fatty acid-binding protein in health-check participants.

Clin Exp Nephrol. 9(1): 34-39, 2005.PubMed

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.

Am J Pathol. 165(4): 1243-1255, 2004.PubMed

Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.

J Lab Clin Med. 143(1): 23-30, 2004.PubMed

SGLT2 阻害薬ルセオグリフロジンの腎機能障害合併2 型糖尿病患者に対する有用性の検討

診療と新薬55, 2018

ヒト腎障害バイオマーカーL-FABP（Liver-Type Fatty Acid-Binding Protein）の非臨床安全性試験への応用

谷本学校 毒性質問箱第19号, 2017

ヒトL型脂肪酸結合蛋白 (L-FABP) キット「ルミパルスL-FABP」の基礎的検討

日本臨床検査自動化学会会誌42(1), 2017

糖尿病腎症・CKDバイオマーカーの有用性 尿中L型脂肪酸結合蛋白(尿中L-FABP)

プラクティス33(3), 2016

糖尿病性腎症の早期診断における尿検査

臨牀と研究93(8), 2016